Stay updated with breaking news from Integrated Summary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Injectafer is an intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, have announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity. The company reported that with this approval, INJECTAFER is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency.
INJECTAFER is now the first and only intravenous iron replacement therapy indicated for adult patients with heart failure who have iron deficiency ... | June 5, 2023
Learn how the clinical trial design and the statistical foundation of the special protocol assessment (SPA), which helped drive the SPA to...
Mansfield, MA (PRWEB) May 26, 2021 -- Mansfield, MA, May 26, 2021 — eClinical Solutions LLC, a global provider of cloud-based enterprise software and